Aniline: Early indicators of toxicity in male rats and their relevance to spleen carcinogenicity

Human and Experimental Toxicology

Volumn 23, Issue 8, 2004, Pages 379-389

  Mellert, W ^a   Deckardt, K ^a   Gembardt, C ^a   Zwirner Baier, I ^b   Jackh R ^a   van Ravenzwaay, Bernard ^a  

^a BASF SE   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Anaemia; Aniline; Inflammation; Iron; Rat; Spleen

Indexed keywords

ANILINE; HEMOGLOBIN; HEMOSIDERIN; IRON; TRANSFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE COUNT; HEINZ BODY; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; IRON BINDING CAPACITY; IRON METABOLISM; KUPFFER CELL; LEUKOCYTOSIS; LIVER TOXICITY; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CANCER; SPLEEN DISEASE; TRANSFERRIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ANEMIA, HEMOLYTIC; ANILINE COMPOUNDS; ANIMALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEINZ BODIES; HEMOGLOBINS; INFLAMMATION; IRON; MALE; RATS; RATS, INBRED F344; SPLENIC NEOPLASMS;

MARTES PENNANTI;

EID: 4444285469     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht466oa     Document Type: Article

References (38)

1. National Cancer Institute. Bioassay for aniline hydrochloride for possible carcinogenicity. CAS No. 142-04-1. ITS Carcinogenesis Technical Report Ser. No. 130. U.S. DHEW, PHS, NIH, Bethesda, MD. DHEW Publ. No. (NIH), 1978: 78-1385.
2. Hazleton Laboratories America Inc. VA. 104 week chronic toxicity study in rats: aniline hydrochloride. Final Report to CIIT; Research Triangle Park, NC, USA, 1982.
3. Hecht SS, El-Bayoumy K, Rivenson A, Fiala ES. Bioassay for carcinogenicity of 3,2′-dimethyll-4-nitro-sobiphenyl, o-nitrosotoluene, nitrobenzene and the corresponding amines in Syrian golden hamsters. Cancer Lett 1983; 20: 349-454.
4. White FR, Eschenbrenner AB, White J. Oral administration of p-aminodimethylaniline, aniline, p-aminoa-zobenzene and the development of tumors in rats. Univ Int Contra Cancrum Acta 1948; 6: 75-78.
5. Druckrey H. Beiträge zur Pharmakologie cancerogener Substanzen - Versuche mit Anilin. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1950; 210: 137.
6. Hagiwara A, Masayuki A, Hirose M, Nakanowatari I, Tsuda H, Ito N. Chronic effects of norharman in rats treated with aniline. Toxicol Lett 1980; 6: 71-77.
7. Bus JS and Popp JA. Perspectives on the mechanism of action of the splenic toxicity of aniline and structurally-related compounds. Food Chem Toxicol 1987; 25: 619-26.
8. Hazelton Labs., America, Inc., VA. A thirty day toxicology study in Fischer-344 rats given aniline HCl. Report to CIIT, Research Triangle Park, NC, USA, Sept. 15, 1977.
9. Goodman DG, Ward JM, Reichardt WD. Splenic fibrosis and sarcomas in F344 rats fed diets containing aniline hydrochloride, p-chloroaniline, azobenzene, o-toluidine hydrochloride, 4,4′-sulfonyldianiline, or D and C Red No. 9. J Natl Cancer Inst 1984; 73: 265-73.
10. Weinberger MA, Albert RH, Montgomery SB. Splenotoxicity associated with splenic sarcomas in rats fed high doses of D and C Red No. 9 or aniline hydrochloride. J Natl Cancer Inst 1985; 75: 681-90.
11. Bus JS, Sun J. Accumulation of covalent binding of radioactivity in rat spleen after 14C-aniline HCl administration. Pharmacologist 1979; 21: 221.
12. Ciccoli L, Ferrali M, Rossi V, Signorini C, Alessandrini C, Comporti M. Hemolytic drugs aniline and dapsone induce iron release in erythrocytes and increase the free iron pool in spleen and liver. Toxicol Lett 1999; 110: 57-66.
13. Khan MF, Boor PJ, Gu Y, Alcock NW, Ansari GAS. Oxidative stress in the splenotoxicity of aniline. Fund Appl Toxicol 1997; 35: 22-30.
14. Khan MF, Green SM, Ansari GA, Boor PJ. Phenylhydroxylamine: role in aniline-associated splenic oxidative stress and induction of subendocardial necrosis. Toxicol Sci 1998; 42: 64-71.
15. Khan MF, Wu X, Alcock NW, Boor PJ, Ansari GAS. Iron exacerbates aniline-associated splenic toxicity. J Toxicol Environ Health 1999; 57: 173-84.
16. Khan MF, Wu X, Boor PJ, Ansari GA. Oxidative modification of lipids and proteins in aniline-induced splenic toxicity. Toxicol Sci 1999; 48: 134-40.
17. Albrecht W, Neumann HG. Biomonitoring of aniline and nitrobenzene. Hemoglobin binding in rats and analysis of adducts. Arch Toxicol 1985; 57: 1-5.
18. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-121.
19. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964; 20: 482-91.
20. Siegel S. Non-parametric statistics for the behavioural sciences. New York, NY: McGraw-Hill, 1956.
21. Hettmannsperger TP. Statistical inference based on ranks. New York, NY: John Wiley & Sons, 1984: 132-42.
22. Miller RG. Simultaneous statistical inference. New York, NY: Springer-Verlag, 1981: 165-67.
23. Nijenhuis A, Wilf SW. Combinatorial algorithms. New York, NY: Academic Press, 1978: 32-33.
24. Neumann HG. Methods for detecting DNA damaging agents in humans: applications in cancer epidemiology and prevention. Lyon: Intern Agency for Research on Cancer, 1988.
25. Birner G, Neumann H-G. Biomonitoring of aromatic amines II: Hemoglobin binding of some monocyclic aromatic amines. Arch Toxicol 1988; 62: 110-15.
26. Neumann HG, Birner G, Sabbioni G. Haemoglobin adducts of aromatic amines as a dosimeter for exposure control and risk assessment. In Garner RC, Farmer PB, Steel GT, Wright AS eds. Human biomonitoring and risk assessment. Oxford, UK: IRL Press at Oxford University Press, 1991: 337-44.
27. Baldwin AS. The Nf-kB and IkB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-81.
28. Schrek R, Rieber P, Bauerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of NF-kB transcription factor and HIV. EMBO J 1991; 10: 2247-58.
29. Barnes PJ, Karin M. Nuclear factor-kB - a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
30. Bours V, Bonizzi G, Bentires-Alj M, Buteau F, Piette J, Lekeux P, Merville MP. NF-kB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology 2000; 153: 27-38.
31. Surh Y-J, Chun K-S, Cha H-H, Han SS, Keum Y-S, Park K-K, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: downregulation of COX-2 and iNOS through suppression of NF.kB activation. Mutat Res 2001; 480: 243-68.
32. Khan MF, Wu X, Wang J. Up-regulation of transforming growth factor-β1 in the spleen of aniline treated rats. Toxicol Appl Pharmacol 2003; 187: 22-28.
33. Cerutti PA. Prooxidant states and tumor promotion. Science 1995; 227: 375-81.
34. Coussens LM, Web Z. Inflammation and cancer. Nature 2002; 420: 860-67.
35. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet 2001; 357: 539-45.
36. Khan MF, Wu X, Ansari GA. Contribution of nitroso-benzene to splenic toxicity of aniline. J Toxicol Environ Health 2000; 60: 263-73.
37. Bomhard EM. High-dose clastogenic activity of aniline in the rat bone marrow and its relationship to the carcinogenicity in the spleen of rats. Arch Toxicol 2003; 77: 291-97.
38. Williams GM, Iatropoulos MJ, Jeffrey AM. Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by DNA-reactive carcinogens 2-acety-laminofluorene and diethylnitrosamine. Toxicol Pathol 2000; 28: 388-95.